Business Context and Reporting Period
Company: Creative Medical Technology Holdings, Inc. (CELZ)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter ended March 31, 2025
Business Overview: A commercial-stage biotechnology company focused on immunotherapy, endocrinology, urology, neurology, and orthopedics. The company markets disposable stem cell concentration kits (CaverStem and FemCelz) and develops "re-programmed" immune cell therapies (ImmCelz) and allogenic cell lines (AlloStem) for conditions including Type 1 Diabetes and chronic lower back pain.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Revenue | $3,000 | $0 |
| Gross Profit | $1,800 | $0 |
| Operating Loss | $(1,660,478) | $(1,123,147) |
| Net Loss | $(1,638,097) | $(1,041,544) |
| Net Loss Per Share (Basic/Diluted) | $(0.83) | $(0.73) |
| Cash and Equivalents (Ending) | $7,702,867 | $9,007,398 |
| Total Assets | $8,347,274 | $6,669,143 |
| Total Liabilities | $286,387 | $327,644 |
| Working Capital | $7,557,624 | $5,807,659 |
Cash Flow Summary (Q1 2025):
- Operating Activities: $(1,591,535)
- Investing Activities: $0
- Financing Activities: $3,354,000 (Net proceeds from warrant exercises)
- Net Increase in Cash: $1,762,465
Material Changes vs. Prior Period
- Revenue Generation: The company recorded $3,000 in revenue for Q1 2025, compared to $0 in Q1 2024, driven by sales of disposable stem cell kits.
- Expense Growth: Operating expenses increased by approximately 48% year-over-year.
- R&D Expenses: Rose 76% to $743,304, primarily due to increased spending on the CELZ-201 ADAPT (Chronic Lower Back Pain) clinical trial.
- SG&A Expenses: Increased 32% to $888,397, driven by higher marketing expenses ($130,851 increase) and insurance costs.
- Capital Raise: In Q1 2025, the company executed a warrant exercise inducement, raising approximately $3.7 million in net proceeds. This contrasts with Q1 2024, which saw no financing proceeds and cash outflows for treasury stock purchases.
- Interest Income: Decreased to $22,381 from $81,603 in the prior year due to lower short-term investment balances.
Outlook, Risks, and Unusual Items
- Clinical Progress:
- CELZ-201 ADAPT (Back Pain): The first cohort of 10 participants completed the study with no serious adverse events. Preliminary blinded data suggests therapeutic potential. The second cohort began treatment in Q1 2025.
- CELZ-201 CREATE-1 (Type 1 Diabetes): FDA cleared for Phase I/II trial; patient recruitment initiated in late 2023.
- Orphan Drug Designation: Received FDA Orphan Drug Designation in March 2024 for Brittle Type 1 Diabetes treatment.
- Warrant Inducement: On March 6, 2025, the company issued new warrants (Inducement Warrants) to holders of existing warrants in exchange for exercising the existing warrants. This transaction is expected to result in a deemed dividend of approximately $3.9 million upon stockholder approval (approved subsequent to period end).
- Liquidity: The company maintains positive working capital of approximately $7.6 million. Management states cash is sufficient for operations, though future capital needs depend on clinical trial progress.
- Risks: The company has a limited operating history, minimal revenue, and relies on external funding. It faces risks related to clinical trial outcomes, regulatory approvals, and competition from better-funded entities.
Investor Verification Checklist
- Warrant Inducement Accounting: Verify the timing and impact of the expected $3.9 million deemed dividend on future earnings and equity.
- Clinical Trial Data: Monitor the release of full, unblinded data from the CELZ-201 ADAPT (back pain) trial to validate preliminary efficacy claims.
- Burn Rate vs. Cash Runway: Assess if the current cash balance of $7.7 million is sufficient to fund ongoing R&D (specifically the back pain and diabetes trials) without further dilution.
- Revenue Sustainability: Confirm if the $3,000 revenue run rate is sustainable or if it represents a one-time transaction, given the company's heavy reliance on financing rather than operations.
- Related Party Transactions: Review ongoing obligations under licensing agreements with related parties (e.g., CMH, Jadi Cell) for potential future cash or stock payment triggers.